Nektar Therapeutics Inc.

Nektar Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in drug discovery and development with a primary focus on immunotherapy. It operates within the biotechnology and healthcare sectors, aiming to innovate treatments for unmet medical needs. The company's pipeline includes novel therapeutic candidates such as REZPEG (NKTR-358), NKTR-422, NKTR-0165, and NKTR-255, reflecting its commitment to advancing immune system modulation. With a relatively small workforce, Nektar plays a role in the research-driven biotechnology landscape, contributing to the broader efforts of developing new medicines that target immune-related conditions. Its activities exemplify the critical intersection of clinical research and pharmaceutical innovation in modern healthcare.